Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · September 15, 2022

Long-Term Safety and Efficacy of Evolocumab in Paediatric Patients With Heterozygous Familial Hypercholesterolaemia

The Lancet Diabetes & Endocrinology


Additional Info

The Lancet Diabetes & Endocrinology
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT
Lancet Diabetes Endocrinol 2022 Sep 05;[EPub Ahead of Print], RD Santos, A Ruzza, GK Hovingh, C Stefanutti, F Mach, OS Descamps, J Bergeron, B Wang, A Bartuli, PS Buonuomo, S Greber-Platzer, I Luirink, AK Bhatia, FJ Raal, JJP Kastelein, A Wiegman, D Gaudet

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading